Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma

van Rensen, E. L. J.; Stirling, R. G.; Scheerens, J.; Staples, K.; Sterk, P. J.; Barnes, P. J.; Chung, K. F.
December 2001
Thorax;Dec2001, Vol. 56 Issue 12, p935
Academic Journal
Background-Interleukin 5 (IL-5) has an important role in mobilisation of eosinophils from the bone marrow and in their subsequent terminal differentiation. A study was undertaken to determine whether inhaled and intravenous IL-5 could induce pulmonary eosinophilia ant bronchial hyperresponsiveness (BHR) independently of these effects. Methods-Nine mild asthmatics receiveed inhaled (15 μg) or intravenous (2 μg) IL-5 or placebo in random order in a double blind, crossover study. Blood samples were taken before and at 0.5, 1, 2, 3, 4, 5, 24, and 72 hours following IL-5 or placebo, and bronchial responsiveness (PC20 methacholine) and eosinophil counts in induced sputum were determined. Results-Serum IL-5 levels were markedly increased 30 minutes after intravenous IL-5 (p0.002), and sputum IL-5 levels increased 4 and 24 hours after inhaled IL-5 (p<0.05). Serum eotaxin was raised 24 hours after intravenous IL-5 but not after inhaled IL-5 or placebo. Blood eosinophils were markedly reduced 0.5-2 hours after intravenous IL-5 (p<0.05), followed by an increase at 3, 4, 5, and 72 hours (p<0.05). Sputum eosinophils rose significantly in all three groups at 24 hours but there were no differences between the groups. Bronchial responsiveness was not affected by IL-S. Conclusion-The effects of IL-5 appear to be mainly in the circulation, inducing peripheral mobilisation of eosinophils to the circulation without any effect on eosinophil mobilisation in the lungs or on bronchial responsiveness.


Related Articles

  • Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. A Straumann // Gut;Jan2010, Vol. 59 Issue 1, p21 

    OBJECTIVE: Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with oesophageal eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was...

  • Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Walsh, Garry M. // Biologics: Targets & Therapy;2013, Vol. 7, p7 

    Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues....

  • Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5-induced eosinophil development. Baruch-Morgenstern, Netali Ben; Shik, Dana; Moshkovits, Itay; Itan, Michal; Karo-Atar, Danielle; Bouffi, Carine; Fulkerson, Patricia C; Rashkovan, Diana; Jung, Steffen; Rothenberg, Marc E; Munitz, Ariel // Nature Immunology;Jan2014, Vol. 15 Issue 1, p36 

    Eosinophilia is a hallmark characteristic of T helper type 2 (TH2) cell-associated diseases and is critically regulated by the central eosinophil growth factor interleukin 5 (IL-5). Here we demonstrate that IL-5 activity in eosinophils was regulated by paired immunoglobulin-like receptors PIR-A...

  • Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention. Zabeau, Lennart; Gevaert, Philippe; Bachert, Claus; Tavernier, Jan // Current Drug Targets - Inflammation & Allergy;Dec2003, Vol. 2 Issue 4, p319 

    Interleukin 5 (IL-5) is the key cytokine in an eosinophil's life span: it supports eosinophilopoiesis and eosinophil differentiation, contributes to eosinophil migration, tissue localisation and function, and prevents eosinophil apoptosis. Given the likely role of eosinophils in chronic...

  • Structure-Based Rationale for Interleukin 5 Receptor Antagonism. Ishino, Tetsuya; Harrington, Adrian E.; Gopi, Hosahudya; Chaiken, Irwin // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1231 

    Human interleukin 5 (IL5) is the major hematopoietin that stimulates the proliferation, migration and activation of eosinophils and is implicated in the pathogenesis of inflammatory and other myeloproliferative diseases. IL5 functions through the signaling of a common receptor subunit...

  • Clarithromycin and pulmonary infiltration with eosinophilia. Terzano, Claudio; Petroianni, Angelo // BMJ: British Medical Journal (International Edition);6/21/2003, Vol. 326 Issue 7403, p1377 

    Describes a patient with asthma referred to a respiratory disease clinic who twice developed fever and pulmonary infiltration with eosinophilia after taking antibiotics. Details of the case; Temporal relation between the patient's symptoms and antibiotic treatment; Diagnosis of drug induced...

  • Role of Eotaxin in Chronic Obstructive Pulmonary Disease (COPD. Al-Midani Adnan; Al-Zain Ammar; Kwatly Khalil // International Journal of Pharmaceutical Sciences Review & Resear;Jul/Aug2013, Vol. 21 Issue 1, p10 

    Eotaxin is a chemokine which characterized by eosinophil chemotactic and activating effects. Eosinophil takes part in airway inflammation in chronic obstructive pulmonary disease (COPD). The aim was to determine eotaxin values as a biomarker in clinical evaluation of COPD patients, and to...

  • Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Grootendorst, Diana C.; Gauw, Stefanie A.; Verhoosel, Renate M.; Sterk, Peter J.; Hospers, Jeannette J.; Bredenbröker, Dirk; Bethke, Thomas D.; Hiemstra, Pieter S.; Rabe, Klaus F. // Thorax;Dec2007, Vol. 62 Issue 12, p1081 

    Background: Roflumilast is a targeted oral once-daily administered phosphodiesterase 4 (PDE4) inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD). Results from in vitro studies with roflumilast indicate that it has anti-inflammatory properties that may be applicable...

  • Objective measures of asthma control: Sputum eosinophils, nitric oxide, and other inflammatory mediators. Lieberman, Phil // Allergy & Asthma Proceedings;Sep/Oct2007, Vol. 28 Issue 5, p510 

    This discussion concerns the tools we can use to measure the status of inflammation in asthma and therefore help us diagnose and manage this condition. Although measurement of pulmonary function is of course a necessity, it does not necessarily tell us the status of activity of the disease. For...


Read the Article


Sign out of this library

Other Topics